Evan Seigerman Analyst Performance

Evan Seigerman is a stock analyst at BMO Capital Markets, covering 11 publicly traded companies across a range of sectors. Over the past year, Evan Seigerman has issued 6 stock ratings, including buy, hold, and sell recommendations. While full access to Evan Seigerman's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Evan Seigerman's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Analyst Rating

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

43 Last 6 Years

Buy Recommendations

48.78% 20 Buy Ratings

Companies Covered

11 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	48.8%	20 ratings
Hold	39.0%	16 ratings
Sell	12.2%	5 ratings

Out of 41 total stock ratings issued by Evan Seigerman at BMO Capital Markets, the majority (48.8%) have been Buy recommendations, followed by 39.0% Hold and 12.2% Sell.

Best & Worst Calls

• Best Call

  000.0%

  REGN

  Dec 2019

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.
• Worst Call

  000.0%

  REGN

  May 2020

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	11 companies

Evan Seigerman, an analyst at BMO Capital Markets, currently covers 11 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 11 companies	100.0%

Evan Seigerman of BMO Capital Markets specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 7 companies	63.6%
PHARMACEUTICAL PREPARATIONS 3 companies	27.3%
MED - DRUGS 1 company	9.1%

Evan Seigerman's Ratings History at BMO Capital Markets

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
VRTX Vertex Pharmaceuticals	8/5/2025	Set Price Target	$472.27	$530.00	Outperform	$0.00 00.00% ROI
INCY Incyte	7/30/2025	Reiterated Rating	$78.05	$60.00	Underperform	$0.00 00.00% ROI
IRON Disc Medicine	5/12/2025	Boost Price Target	$47.07	$120.00	Outperform	$0.00 00.00% ROI
NBIX Neurocrine Biosciences	5/6/2025	Boost Price Target	$125.03	$115.00	Market Perform	$0.00 00.00% ROI
GILD Gilead Sciences	2/12/2025	Boost Price Target	$103.85	$115.00	Outperform	$0.00 00.00% ROI
VRTX Vertex Pharmaceuticals	1/31/2025	Set Price Target	$484.24	$545.00		$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.